Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Firebrick Pharma Limited ( (AU:FRE) ) just unveiled an announcement.
Firebrick Pharma Limited has announced the commencement of manufacturing for its new product, Nasodine Throat Spray, which will be exported starting November 2025. This new product, a 1.0% povidone-iodine formulation, offers a convenient alternative to traditional throat gargles and will first be launched in Singapore. The company has received export approval from the TGA and plans to market the product through its licensing partner, Innorini Life Sciences, targeting healthcare professionals and retail channels by mid-2026. This expansion marks the first new addition to the Nasodine range since the Nasodine Nasal Spray, signaling future growth in the brand’s product line.
More about Firebrick Pharma Limited
Firebrick Pharma is a pharmaceutical innovator focused on developing and commercializing novel formulations and uses of povidone-iodine (PVP-I). The company has launched products like Nasodine Nasal Spray and is expanding its product range with several other developments.
Average Trading Volume: 94,045
Technical Sentiment Signal: Sell
See more data about FRE stock on TipRanks’ Stock Analysis page.